OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Files An 8-K Other EventsITEM 8.01 OTHER EVENTS
The Company completed its previously-announced note repurchase, purchasing approximately 35,000 individual Notes (as defined below) with approximately $35.0 million in face value of its 2.75% Convertible Senior Notes due 2020 (the “Notes”) for approximately $10 million. This settlement amount corresponded to an effective purchase price of 28.25% of par, including fees.
About OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX)
Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER. OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Recent Trading Information
OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) closed its last trading session up +0.01 at 1.68 with 273,035 shares trading hands.